BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Datamonitor Report: Rapidly Deteriorating Growth for Pharma


1/20/2011 9:54:26 AM

January 2011 -- Growth will slow to just 1.3% to 2015 for the branded prescription pharmaceutical industry’s leading companies, according to latest research from independent market analyst, Datamonitor.

Between 2003 and 2009, theses same companies enjoyed robust sales growth at a compound annual growth rate (CAGR) of 7.1%. Sharp declines in branded sales following the loss of patent exclusivity will drive this rapid deteroation in growth.

Simon King, pharmaceutical company analyst at Datamonitor, comments: “The difficulty in developing new products, particularly those that can generate sufficient sales to compensate for blockbuster expiries, has compounded this problem. This has driven a steady shift away from blockbuster-centric growth strategies towards diversification into other areas of the market.

“Datamonitor predicts that those companies insulated from generic competition—or able to offset it via revenue growth sourced from a high biologics focus or the targeting of niche indications and areas of high unmet need will therefore emerge as the best performers.”

Bayer, Novartis, Roche and GlaoxSmithKline wil be the only Big Pharma companies generating above average growth over the period to 2015; Datamonitor estimates a CAGR of 3.9%, 3.6% AND 2.6% respectively.

Of 43 branded companies examined in detail by Datamonitor, 11 are expected to report a negative sales CAGR over the period to 2015. Of those expected to deliver a positive sales CAGR, only six will exceed the 7.1% average shown between 2003 and 2009.

John Shortmoor & Simon King will be leading a webinar to discuss the findings of the complete report on 25th January 2011

Based on the report: Pharmaceutical Company Outlook to 2015

Simon King is available for comment.

To arrange an interview or for further details regarding this release please contact Joe Dixonin the Datamonitor press office on + 44 (0)161 238 4082, or email jdixon@datamonitor.com

ABOUT DATAMONITOR

The Datamonitor Group (www.datamonitor.com) is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Sourcing, Technology and Telecoms industries. Combining our industry knowledge and experience, we assist more than 6,000 of the world’s leading companies in making better strategic and operational decisions.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES